Bio-Rad Laboratories, Inc has launched a range of anti-vedolizumab antibodies to be used to support research into the treatment of ulcerative colitis (inflammatory bowel disease) and Crohn’s disease. Vedolizumab (Entyvio) is a monoclonal antibody used to treat these diseases and Bio-Rad’s anti-vedolizumab antibodies include four recombinant monoclonal anti-idiotypics that are highly specific for this humanised IgG1 kappa drug, making them highly suitable for the development of bioanalytical and patient monitoring assays.
The anti-vedolizumab antibodies are generated using Bio-Rad’s Human Combinatorial Antibody Library (HuCAL) and CysDisplay, a proprietary method of phage display, resulting in highly targeted reagents. These paratope-specific antibodies inhibit the binding of vedolizumab to its target, alpha4beta7 integrin, which makes them ideal for development of a pharmacokinetic bridging ELISA to monitor free drug levels, or as reference standards in anti-drug antibody assays. In addition, their recombinant production method ensures a consistent and secure supply.
The new antibodies are approved for in-vitro research purposes and for commercial applications for the provision of in-vitro testing services to support preclinical and clinical drug development and patient monitoring.
For further information about Bio-Rad visit www.bio-rad.com
Latest from Tom Mulligan
- SGS’s first malaria human challenge trial will take place in Belgium this month
- TC BioPharm creates allogeneic cell banks for CAR-T cancer therapy products
- Horizon Discovery extends CRISPR Screening Service to primary human T cells
- TrakCel and The Quick Life Science Group partner on supply chain IT solution for cell and gene therapies
- Almac Group extends personalised cancer vaccine production facilities
- Cobra Biologics appoints Dr Darrell Sleep as Director of Innovation
- Phico Therapeutics appoints financial director and two non-executive directors
- Evonetix appoints Stephanie Brooking as Head of Product Management
- Bio-Rad publishes new findings on generation and characterisation of drug-target-complex-specific antibodies
- Expedeon licenses Lightning-Link rapid biotinylation technology to Cell Guidance Systems